Background: Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema).
Methods: Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum.
Results: Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions. Conclusions: These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.
Over the past decade there has been intensive interest in understanding immunity to poxviruses at multiple levels, with much of the effort focused on understanding the potent immunity elicited by the smallpox vaccine and the requirements for protection against smallpox and related pathogenic poxviruses [1] . From a clinical perspective, updating and stockpiling smallpox vaccine has been a major focus [2] , as has been the development of anti-smallpox therapeutics. Two categories of anti-smallpox therapeutics have been extensively explored for potential biodefence use against smallpox itself or rare severe side effects of smallpox vaccination: small molecule drugs [3] [4] [5] and monoclonal antibodies (mAbs) [6] [7] [8] [9] .
A clonal isolate of vaccinia virus (VACV) NYCBOH , ACAM2000, has now been developed as a cell-culturederived smallpox vaccine, with a comparable immunogenicity and safety profile to Dryvax [2] . Smallpox vaccine 'take' for classic VACV NYCBOH , ACAM2000 or Lister is observed as the formation of a pustule starting on approximately day 5 post-vaccination and lasting for 1-2 weeks thereafter [10, 11] . The vaccine provides outstanding immunity, but causes a variety of side effects that have been reason for concern [12] . Common side effects include fever and satellite pocks (additional pustules near the primary pustule) [11, 12] . More severe side effects include progressive vaccinia, generalized vaccinia, encephalitis, vaccinia keratitis and eczema vaccinatum [12] . Eczema vaccinatum is a severe and difficult to treat pathology that occurs in some immunized humans with a previous history of atopic dermatitis (eczema). Currently, vaccinia immune globulin (VIG) is the only licensed therapeutic to treat severe side effects of smallpox vaccination [13] . In addition, VIG has shown efficacy against smallpox itself, in clinical trials in the early 1960s [14] . Unfortunately, VIG is a poorly characterized, variable human product that is of limited potency [13, 14] . These limitations of VIG have led to great interest in the development of an alternative high-potency anti-vaccinia and anti-smallpox immunotherapy.
Poxviruses have two distinct virion forms, intracellular mature virions (IMV; MV) and extracellular
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Protective murine and human monoclonal antibodies against eczema vaccinatum [1] . VIG contains both anti-MV and anti-EV antibodies [15] [16] [17] . Therefore, we have pursued development of a VIG replacement therapeutic product containing one anti-MV mAb and one anti-EV mAb, each capable of neutralizing their respective virion form [6] . We first identified murine and human neutralizing antibodies against the MV surface antigen H3 [16, 17] and the EV surface antigen B5 [7, 18] , both of which neutralize in the presence of complement. We further demonstrated that B5 antibodies are highly effective at catalyzing complement-mediated killing of VACV-infected cells as an additional antiviral mechanism [7, 18] . Recently, we demonstrated that anti-H3 and anti-B5 murine and human mAbs were significantly more effective than VIG at extending lifespan of immunodeficient SCID mice infected with VACV [6] . As a second model of treatment efficacy, we examined the efficacy of anti-H3 and anti-B5 mAbs against VACV in a new mouse model of eczema vaccinatum.
Methods

Viruses
VACV strain Western Reserve (VACV WR ) stocks were grown as previously described [16, 17] . The ACAM2000 stock was generated by single passage amplification in HeLa cells of ACAM2000 ® virus vaccine (Acambis, Cambridge, MA, USA).
Mouse infections
NC/Nga mice were used in all experiments [19] . Eczematous skin lesions were induced as described previously [20] . Briefly, back skin was shaved and dermatitis was induced by two rounds of treatment with Dermatophagoides farinae extract (Greer Laboratories, Lenoir, NC, USA) and Staphylococcal enterotoxin B (SigmaAldrich, St Louis, MO, USA). During this treatment, the back skin was occluded with a bandage that was removed the following week. Clinical scores of eczematous skin lesions are based on severity (0, no signs; 1, mild; 2, intermediate; and 3, severe) of four signs (redness, bleeding, eruption and scaling). Scoring of skin lesions was performed in a blind manner. VACV (VACV WR or ACAM2000; 10 6 plaque-forming units per 3 µl) was dropped on the centre of skin lesions of mice with a clinical score of ≥7 (eczematous group) followed by pricking 15 times with a 27G needle. In some experiments, a cohort (normal group) of age-and sex-matched mice with healthy skin was also infected at the same anatomical site. After VACV infection on day 0, mice were monitored daily in a blind manner and body weight and size of the skin lesion were measured. Murine anti-VACV mAbs anti-B5 number B126 and/or anti-H3 number 41 were intraperitoneally or intravenously injected 24 h before or 12 h after VACV infection. Animals were housed in microisolator cages in ventilated racks. All animal experiments were conducted using the Institutional Animal Care and Use Committee approved animal protocols.
Antibodies
Anti-B5 IgG2a clone B126 and anti-H3 IgG2a clone 41 were generated and produced as previously described [6, 18] . Fully human mAbs h101 and hV26 were generated and produced as described [6, 7] . Anti-DNP IgG1 is specific for the hapten DNP.
Statistical analyses
Statistical analyses were carried out using Prism 5.0 software (GraphPad, San Diego, CA, USA). Size of skin lesions, incidence and changes of body weight were analysed with unpaired two-tailed Student's t-tests. Cumulative skin lesion burden was calculated as the area under the curve of skin lesion size over time and analysed by unpaired two-tailed Student's t-tests. P<0.05 was considered statistically significant. Disease incidence (prevalence) statistical significance was determined by Fisher's exact test.
Results
NC/Nga eczema vaccinatum model
Eczema vaccinatum is a severe, potentially fatal, side effect of smallpox vaccination that occurs in some vaccinees with a previous history of eczema. The reason for this striking and peculiar pathology of VACV has been unclear. Previously, no small animal model of this clinical disease had been available. We recently developed a mouse model of eczema vaccinatum [21] . NC/ Nga mice are susceptible to atopic dermatitis [19, 20] . In this system, NC/Nga mice were shaved and atopic dermatitis was induced with allergen ( Figure 1A and 1B). Eczematous mice were then infected intradermally with VACV WR , and virus-induced skin lesions were observed ( Figure 1C ). Viral titres in the skin lesions were >100-fold increased in eczematous mice [21] , and the disease was strongly associated with defective natural killer (NK) cell activity and increased interleukin (IL)-17 levels [21] . The infection and eczema vaccinatum lesions were self-resolved after 2 weeks (Figure 2A ). Eczema vaccinatum can also be induced with vaccine strain viruses, although the skin lesions are less severe, consistent with the low replicative potential of VACV NYCBOH -related strains (for example, ACAM2000) in mice ( Figure 1D ).
Protective efficacy of single murine anti-VACV mAbs
The protective efficacy of murine mAbs against VACV at treating eczema vaccinatum was first tested in a preexposure model wherein eczematous mice were injected with a single 200 µg anti-H3 or anti-B5 mAb 1 day prior to intradermal infection with VACV. It was unclear whether antibodies would be effective against intradermal infection with VACV, particularly given the defective NK cells, which are important for early control of the virus. Development of skin lesions was delayed in mAb-treated mice ( P<0.01 at all time points from day 2-14; anti-H3, P≤0.01 at all time points from day 2-13, except day 3 and P<0.05 at days 3 and 14; Figure 2A ). Disease incidence was moderately reduced, from 100% to 80% in anti-H3-or anti-B5-treated mice ( Figure 1C ). Lesion disease burden was significantly reduced after treatment with either anti-H3 mAb (P<0.001) or anti-B5 mAb (P<0.001). Minimal change in body weight was observed in all groups ( Figure 2D ), consistent with our previous work [21] .
Post-exposure prophylaxis efficacy of the antibodies was then tested. Eczematous mice were infected intradermally with VACV. Intravenous injection of anti-H3 or anti-B5 mAb was done 12 h after infection. Anti-B5 treatment was still able to delay lesion development (P<0.05, day 3; Figure 3A and 3C), reduce the disease incidence ( Figure 3C ) and reduce the overall lesion disease burden (P<0.05; Figure 3B ). Anti-H3 was not able to reduce disease incidence when provided after infection (P=NS, day 3; Figure 3C ), nor did it provide a statistically significant reduction in overall lesion disease burden ( Figure 3B ). Anti-H3 treatment post-infection did provide some reduction in lesions, though this trend was not statistically significant ( Figure 3A and 3B) . These data in combination with the pre-exposure data shown in Figure 1 after initiation of infection. This is likely due to lack of neutralization of the EV form.
Protective efficacy of murine anti-VACV mAb combination therapy
Given that anti-B5 exhibited good efficacy and anti-H3 exhibited some efficacy in post-exposure treatment, a combination of anti-B5 and anti-H3 was then tested. This combination neutralizes both EV and MV virions and is the proposed regimen for humans [6] . Mice treated with anti-B5 mAb alone post-exposure were again partially protected from disease, indicated by reduction in peak skin lesion size (P<0.05, each time point from days 4-7; Figure 4A ), delayed onset of disease (P=0.01; Figure 4C ) and overall lesion disease burden reduction (P<0.05; Figure 4B ). Mice treated with the anti-B5/H3 combination were in much better health than mice treated with anti-B5 alone. Greatly reduced lesion sizes (P≤0.01, days 4-14; Figure 4A ) and overall lesion disease burden was observed in mice receiving the anti-B5/H3 combination (P<0.01 versus control; P<0.05 versus anti-B5 mAb alone; Figure 4B ). Most strikingly, disease was completely prevented in approximately one-half of the animals receiving the anti-B5/H3 mAb combination ( Figure 4C ). This was somewhat unexpected, given the poor efficacy of anti-H3 mAb single therapy post-exposure (Figure 3) . Together, these data ( Figures 3 and 4 
Protective efficacy of human anti-VACV mAbs
Given the successful activities of murine anti-B5 and anti-H3 mAbs against VACV in vitro and in vivo in earlier studies [6, 18] and against eczema vaccinatum ( Figures 2, 3 and 4) , we developed fully human anti-B5 and anti-H3 mAbs as potential therapeutics [6, 7] . Using the eczema vaccinatum model, mice were treated with mAbs after initiation of intradermal VACV infection. A single inoculation of human anti-B5 mAb was provided alone or in combination with a human anti-H3 mAb. Mice that received postexposure treatment with human anti-B5 mAb alone were partially protected from disease, indicated by a reduction in peak skin lesion size (P<0.05, day 4; Figure 5A and 5B), delayed onset of disease (P<0.05; Figure 5A ), lower disease incidence ( Figure 5C ) and overall lesion disease burden reduction (P<0.01; Figure 5B ). Mice treated with the human anti-B5/ H3 mAb combination exhibited protection. Greatly reduced lesion sizes (P≤0.01, days 2-12; Figure 5A ) and overall lesion disease burden was observed in mice receiving the anti-B5/H3 combination (P<0.001 versus control; P<0.01 versus anti-B5 mAb alone; Figure 5A) . Disease was completely prevented in approximately one-half of the animals receiving the anti-B5/ H3 mAb combination (P<0.01; Figure 5C ). Together, these data recapitulate our murine mAb findings shown in Figure 4 , demonstrating that targeting both EV and MV neutralization mAbs results in increased protection in vivo. 
Discussion
Our primary goal was preclinical validation of a postexposure prophylactic human anti-MV and anti-EV mAb combination treatment that would be a replacement for VIG as treatment for eczema vaccinatum and other severe side effects of vaccinia immunization, and potentially for treatment of smallpox infection itself. The rationale for this approach is that mAbs can have much higher specific activity than polyclonal antibodies, and recombinant human mAbs can be manufactured in virtually unlimited quantities, under well-defined conditions. Here, we show that neutralizing mAbs against VACV can be highly efficacious at ameliorating or eliminating eczema vaccinatum in a small animal model. Eczema vaccinatum is associated with poor NK cell activity and high levels of IL-17, resulting in vastly increased viral loads and progressive skin lesion development [21] . Our data indicate that reduction in the viral load by neutralizing antibodies offsets the defective antiviral activity of the NK cells, likely resulting in clearance of the infection by normal innate and adaptive mechanisms of the immune system independent of NK cells. Reduction in viral load by these neutralizing antibodies would therefore be likely to be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine. We speculate that the combination of anti-H3 and anti-B5 mAbs provides increased protection in this eczema vaccinatum model, and in an immunodeficient mouse model, via several mechanisms of action. The anti-H3 mAb neutralizes MV virions [6] , which are released from dead cells in abundance. The anti-B5 mAb neutralizes the other virus form, EV virions, in a complement-dependent manner [7, 18] . In addition, anti-B5 mAbs direct the complement-mediated killing of VACV-infected cells, because of expression of B5 on the surface of infected cells [7, 18] . This is a potent mechanism of eliminating reservoirs of replicating virus. Of interest, we cannot exclude the possibility that a defect in NK cell antibody-dependent cellular cytotoxicity is one component of the NK cell defect observed in eczema-prone Nc/Nga mice [21] . It is also plausible that the anti-H3 mAbs specifically enhance the function of anti-B5. Anti-B5 mAbs can direct killing of VACV-infected cells, but that then can release a bolus of MV virions, and the presence of anti-H3 mAbs eliminates that problem. In addition, the outer membrane of EV particles is notoriously fragile [22] [23] [24] [25] , and binding of anti-B5 mAb to EV virions might, in some cases, disrupt the EV membrane and release the infectious MV particle inside. Again, the presence of anti-H3 mAb compensates for this problem by simultaneously neutralizing the MV. Given the efficacy of these mAbs in three animal models -eczema vaccinatum, respiratory VACV [7] and immunodeficient SCID mice [6] -and their enhanced efficacy in comparison to VIG [6] , these human mAbs might also be efficacious against smallpox.
